PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

NCT03120000 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Withdrawn

Conditions

Primary Central Nervous System Lymphoma

Interventions

DRUG: PQR309

Sponsor

PIQUR Therapeutics AG